Back Home About Us

CROI 2017: Better Depression Care Could Improve Outcomes for HIV Treatment Programs

Improved management of depression and other mental health problems has the potential to improve the outcomes of HIV treatment programs, Pamela Collins of the U.S. National Institute of Mental Health reported at the recent Conference on Retroviruses and Opportunistic Infections in Seattle. Mental health treatment should be integrated into HIV services in resource-limited settings, she said.

alt

Read more:

CROI 2017: Peer Navigators Improve Linkage to HIV Care and Retention in South African Study

Adults recently diagnosed with HIV who get help from peers to address personal barriers to care together with SMS check-in messages, appointment, and healthy living reminders had nearly twice the odds of being retained in care at 1 year of follow-up compared to those getting standard care at primary health clinics in South Africa according to findings presented at the recent Conference on Retroviruses and Opportunistic Infections.

alt

Read more:

CROI 2017: Long-Term Darunavir/Ritonavir Modestly Increases Risk of Cardiovascular Disease

Long-term use of the boosted protease inhibitor darunavir (Prezista) modestly increases the risk of cardiovascular disease, according to data from the ongoing D:A:D study presented to the recent Conference on Retroviruses and Opportunistic Infections. Investigators identified an independent association between cumulative use of the drug over 5 years and heart attack and stroke.

alt

Read more:

CROI 2017: Finding Men with HIV -- and Keeping Them in Treatment

Specialized services to attract men to HIV testing and treatment may need to adopt several different formats in order to reach different sub-populations of men, suggesting there is no single service innovation that will boost uptake among men in sub-Saharan Africa, according to research from South Africa presented at last month’s Conference on Retroviruses and Opportunistic Infections.

alt

Read more:

CROI 2017: Dolutegravir Monotherapy Fails to Maintain Viral Suppression

Dolutegravir used alone without other antiretrovirals was unable to keep viral load suppressed in some people who switched from a standard 3-drug combination regimen, according to research presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) last month in Seattle. But evidence continues to show that dolutegravir plus a single other drug can work well as maintenance therapy.

alt

Read more:

CROI 2017: How Does Vedolizumab Antibody Therapy Lead to Sustained Viral Remission?

HIV and its monkey cousin SIV can carry the alpha-4 beta-7 integrin receptor in their outer envelope, which helps the virus enter gut cells during early infection, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. This finding may help explain how an antibody against alpha-4 beta-7 produced sustained viral remission in monkeys.

alt

Read more:

CROI 2017: Integrase Inhibitors May Increase Risk of IRIS in Late Presenters for HIV Treatment

HIV integrase inhibitors such as dolutegravir and raltegravir may increase the risk of immune reconstitution inflammatory syndrome or IRIS, according to studies from the Netherlands and France presented last month at the Conference on Retroviruses and Opportunistic Infections in Seattle.

alt

Read more:

CROI 2017: Bone Density Improves in People Who Switch from Tenofovir DF to Tenofovir Alafenamide

After 3 years, tenofovir alafenamide (TAF) for first-line HIV treatment was better at suppressing viral load and safer for the bones and kidneys than the older tenofovir disoproxil fumarate (TDF), researchers reported at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) last month in Seattle. Another study showed that people with low bone density who switched from TDF to TAF saw improved bone health, including a reduction in osteoporosis.

alt

Read more:

CROI 2017: HIV's Milder Cousin May Be Less Mild than Previously Thought

The virulence of HIV-2 virulence may have been underestimated, and although progression to AIDS and death in people with HIV-2 infection was slower than with HIV-1, it was the rule rather than the exception -- 70% progressed to AIDS within 20 years -- according to new research from West Africa presented at last month's Conference on Retroviruses and Opportunistic Infections.

alt

Read more: